Generic Name and Formulations:
Dipivefrin HCl 0.1%; oph. soln; contains benzalkonium chloride.
Indications for PROPINE:
Initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
1 drop every 12 hrs. Transferring from antiglaucoma agents other than epinephrine: on the first day continue previous medication and add 1 drop of Propine in each eye every 12 hours; on the following day, discontinue previous antiglaucoma agent. Transferring from conventional epinephrine therapy: discontinue epinephrine medication and institute Propine regimen. If additional therapy is required, add 1 drop of Propine every 12 hours to other antiglaucoma agents. Concomitant therapy: may add Propine to pilocarpine, carbachol, echothiophate iodide or acetazolamide for difficult to control patients.
Aphakic patients are at increased risk of developing maculopathy; monitor visual acuity closely. Cardiovascular disease. Hypertension. Pregnancy (Cat.B). Nursing mothers.
Local effects (eg, injection, burning, stinging, follicular conjunctivitis, pain, mydriasis, blurry vision, pruritus, adrenochrome deposits in the conjunctiva and cornea), headache, allergic reaction, cardiovascular effects (eg, tachycardia, arrhythmias, hypertension).
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML